Myelodysplastic Syndrome Drugs Market Forecasted to Reach USD $3.84 Billion by 2030 at 9.6% CAGR


 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Does the Market Size of the Myelodysplastic Syndrome Drugs Market in 2030 Compare With That of 2026?
The myelodysplastic syndrome drugs market size has grown strongly in recent years. It will grow from $2.44 billion in 2025 to $2.66 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to limited availability of targeted mds therapies, reliance on blood transfusions, low awareness of mds subtypes, limited r&d investments, high treatment costs in emerging markets.

The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to rising incidence of mds due to aging populations, increased investment in precision medicine, advancements in genomics-based therapies, growing healthcare infrastructure in apac, expansion of reimbursement policies for mds drugs. Major trends in the forecast period include personalized mds therapies, increased adoption of erythropoiesis-stimulating agents (esas), expansion of outpatient treatment centers, growing preference for parenteral administration, rising focus on generic mds drug development.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

What Are the Most Significant Drivers Affecting the Myelodysplastic Syndrome Drugs Market Expansion?
Rising demand for personalized medicine is expected to propel the growth of the myelodysplastic syndrome drugs market going forward. Personalized medicine is a medical approach that involves dividing individuals into separate groups based on their medical history, genetic profile, and other factors. For myelodysplastic syndrome, personalized medicine involves tailoring treatment based on an individual's unique genetic and molecular characteristics. This helps to optimize therapeutic outcomes and minimize adverse effects when managing this heterogeneous hematological disorder. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the myelodysplastic syndrome drugs market.

How Is the Myelodysplastic Syndrome Drugs Market Arranged by Segment Classification?
The myelodysplastic syndrome drugs market covered in this report is segmented –

1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products

What Are the Most Prominent Trends Impacting the Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market are developing telomerase inhibitors to target the enzyme telomerase, aiming to slow down the progression of the disease by limiting the uncontrolled division of abnormal cells. Telomerase inhibitors are helpful in myelodysplastic syndrome drugs as they work by inhibiting the enzyme telomerase, which slows the proliferation of abnormal cells, potentially improving patient outcomes. For instance, in June 2024, Geron Corporation, a US-based biotechnology company, launched rytelo (imetelstat), an FDA-approved intravenous telomerase inhibitor for adults with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion dependent anemia unresponsive to and ineligible for ESA. Rytelo offers durable transfusion independence, improved hemoglobin levels, and addresses an unmet need in the myelodysplastic syndrome drugs market with a manageable safety profile.

Who Are the Most Influential Players in the Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market are Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, AbbVie Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Teva Pharmaceutical Industries Ltd., Incyte Corporation, MEI Pharma Inc.

Get the full myelodysplastic syndrome drugs market report here:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Which regions are expected to dominate the Myelodysplastic Syndrome Drugs Market during the forecast period?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2025. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Post a Comment

Popular posts from this blog

Train And Components Market Report 2025 – Strategic Data for Growth and Expansion

Image
  Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts. What is the anticipated market size of the train and components industry over the next few years? The train and components market size has grown strongly in recent years. It will grow from $245.66 billion in 2024 to $266.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to economic conditions, urbanization, government investment, environmental concerns. The train and components market size is expected to see strong growth in the next few years. It will grow to $354.13 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to high-speed rail expansion, sustainable transport, electrification, freight rail expansion, regulatory compliance. Major trends in the forecast period include electrification and lightweighting, advan...
Read more

Global Fire Retardant Welding Blanket Market Report 2025: Market Opportunities & Challenges Outlook

Image
  For organizations targeting expansion, this report delivers actionable intelligence on how the fire retardant welding blanket industry is evolving. How Big Is The Fire Retardant Welding Blanket Market In 2025? The fire retardant welding blanket market size has grown strongly in recent years. It will grow from $1.22 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising use of asbestos alternatives in thermal protection, growing deployment of welding blankets in shipbuilding, increasing fire incidents in manufacturing facilities, rising preference for reusable fire safety equipment, and growing reliance on manual welding techniques. The fire retardant welding blanket market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing a...
Read more

Construction Market Outlook 2025 – In-Depth Data for Business Expansion to 2034

Image
Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts What is the current market size of the construction industry, and what growth rate is it expected to achieve? The construction market size has grown strongly in recent years. It will grow from $16152.39 billion in 2024 to $17045.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to the increasing infrastructure development, the increase in renovation activities, rapid growth in the elderly population, and the rise in domestic manufacturing. The construction market size is expected to see strong growth in the next few years. It will grow to $21260.28 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising urbanization, increasing population growth, increasing government support, rising industrialization, and an increase ...
Read more